


PRODUCT INFORMATION



LY2109761

Item No. 15409

CAS Registry No.: 700874-71-1
Formal Name: 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]-quinoline
MF: C₂₆H₂₇N₅O₂
FW: 441.5
Purity: ≥98%
UV/Vis.: λ_{max}: 236 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LY2109761 is supplied as a crystalline solid. A stock solution may be made by dissolving the LY2109761 in the solvent of choice, which should be purged with an inert gas. LY2109761 is soluble in organic solvents such as ethanol and DMSO. The solubility of LY2109761 in these solvents is approximately 2 and 0.1 mg/ml.

Description

LY2109761 is a small molecule inhibitor of the TGF-β receptor type 1/type II kinases (IC₅₀ = 69 nM).¹ It has been used to study the role of TGF-β signaling in tumor cell migration and metastasis in pancreatic tumor cell lines where 5 μM of the compound completely disrupts Smad-2 phosphorylation, an immediate downstream target of the kinase activity.² It can also suppress radiation-induced inflammatory cytokine signaling and proangiogenic genes, including ID1, in human primary fibroblasts.³

References

1. Li, H., McMillen, W.T., Heap, C.R., *et al.* Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors: Discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent. *J. Med. Chem.* **51(7)**, 2302-2306 (2008).
2. Melisi, D., Ishiyama, S., Scwab, G.M., *et al.* LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. *Mol. Cancer Ther.* **7(4)**, 829-840 (2008).
3. Flechsig, P., Dadrich, M., Bickelhaupt, S., *et al.* LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. *Clin. Cancer Res.* **18(13)**, 3616-3627 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM